Core Viewpoint - Rosen Law Firm is reminding investors who purchased Paragon 28, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Paragon 28 securities class action is from May 5, 2023, to August 8, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by November 29, 2024, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Paragon 28 made materially false and misleading statements regarding its financial statements and internal controls [5]. - It is claimed that the company understated issues with its internal controls, leading to misleading statements about its business and prospects [5]. - The lawsuit asserts that investors suffered damages when the true details about the company's situation became public [5].

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Flux Power Holdings, Inc. (NASDAQ: FLUX) between November 11, 2022 and September 30, 2024, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 31, 2024 in the securities class action first filed by the Firm. ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the “Class Period”), of the important December 13, 2024 lead plaintiff deadline. SO WHAT: If you purchased Edwards securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

Company Performance - CS Disco reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of 33.33% [1] - The company posted revenues of $36.27 million for the quarter ended September 2024, slightly missing the Zacks Consensus Estimate by 0.04%, but showing an increase from $34.94 million a year ago [2] - Over the last four quarters, CS Disco has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Movement and Outlook - CS Disco shares have declined approximately 20.2% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $36.99 million, and -$0.32 on revenues of $144.81 million for the current fiscal year [7] Industry Context - The Internet - Software industry, to which CS Disco belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of CS Disco's stock may also be influenced by the overall industry outlook and trends [8]

DISCO Announces Third Quarter 2024 Financial Results Total Revenue of $36.3 Million, A Year over Year Increase of 4% AUSTIN, Texas - November 6, 2024 - CS Disco, Inc. ("DISCO") (NYSE: LAW) today announced financial results for its third quarter ended September 30, 2024. "As we continue to focus on the customer experience, operational effectiveness and revenue acceleration, I am excited about the path forward for DISCO with continued product innovation," said CEO Eric Friedrichsen. "DISCO's combination of AI ...

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) between February 28, 2020 and October 18, 2024, both dates inclusive (the “Class Period”) of the important December 16, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Acadia Healthcare securities during the Class Period you may be entitled to compensation without ...

NEW YORK, Nov. 03, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Flux Power Holdings, Inc. (NASDAQ: FLUX) between November 11, 2022 and September 30, 2024, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 31, 2024 in the securities class action first filed by the Firm. ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Outset Medical, Inc. securities between August 1, 2022, and August 7, 2024, of the upcoming lead plaintiff deadline on October 28, 2024, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Outset Medical securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [1][4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [2]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [2]. Group 3: Allegations Against Outset Medical - The lawsuit alleges that during the Class Period, Outset Medical made false or misleading statements regarding its Tablo products, including marketing for unapproved uses and lacking the necessary sales team to support revenue growth [3]. - The claims suggest that these misrepresentations led to investor damages when the true details became public [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased AMMO, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the AMMO securities is from August 19, 2020, to September 24, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by November 29, 2024 [1][4] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [2] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company [2] - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [2] Group 3: Allegations Against AMMO, Inc. - The lawsuit alleges that AMMO made false or misleading statements and failed to disclose critical information regarding its financial reporting and internal controls [3] - Specific allegations include inadequate internal controls, failure to disclose executive officers, and mischaracterization of fees related to investor relations [3] - The misleading statements led to investor damages when the true details were revealed [3]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Elanco Animal Health Incorporated securities during the specified Class Period, indicating potential legal issues for the company related to misleading statements and safety concerns regarding its products [1][5]. Group 1: Class Action Details - The class action lawsuit is filed for securities purchased between November 7, 2023, and June 26, 2024, and interested parties must act by December 6, 2024, to serve as lead plaintiff [1][3]. - Investors who purchased Elanco securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Allegations Against Elanco - The lawsuit claims that Elanco made false and misleading statements regarding the safety of Zenrelia, a JAK inhibitor for canine dermatology, and its likelihood of meeting approval timelines for Zenrelia and another product, Credelio Quattro [5]. - It is alleged that Elanco's business and financial prospects were overstated, leading to materially false public statements throughout the Class Period [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest ever against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].